BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sung KC, Ryu S, Lee JY, Kim JY, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol 2016;65:791-7. [PMID: 27255583 DOI: 10.1016/j.jhep.2016.05.026] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Khanna S, Wilkins JT, Ning H, Allen NB, Lewis CE, Carr JJ, Lloyd-jones D, Vanwagner LB, Hirata MH. Lipoprotein Levels in Early Adulthood and NAFLD in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Journal of Nutrition and Metabolism 2022;2022:1-9. [DOI: 10.1155/2022/1727711] [Reference Citation Analysis]
2 Yoo TK, Oh BK, Lee MY, Sung KC. Association between physical activity and insulin resistance using the homeostatic model assessment for insulin resistance independent of waist circumference. Sci Rep 2022;12:6002. [PMID: 35397649 DOI: 10.1038/s41598-022-10032-2] [Reference Citation Analysis]
3 Choi HI, Lee MY, Kim H, Oh BK, Lee SJ, Kang JG, Lee SH, Kim BJ, Kim BS, Kang JH, Lee JY, Sung KC. Effect of physical activity on the development and the resolution of nonalcoholic fatty liver in relation to body mass index. BMC Public Health 2022;22:655. [PMID: 35382785 DOI: 10.1186/s12889-022-13128-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schnurr TM, Katz SF, Justesen JM, O'Sullivan JW, Saliba-Gustafsson P, Assimes TL, Carcamo-Orive I, Ahmed A, Ashley EA, Hansen T, Knowles JW. Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. Hepatol Commun 2022. [PMID: 35293152 DOI: 10.1002/hep4.1932] [Reference Citation Analysis]
5 Donnelly MC, Stableforth W, Krag A, Reuben A. The Negative Bidirectional Interaction Between Climate Change and the Prevalence and Care of Liver Disease: A Joint BSG, BASL, EASL, and AASLD Commentary. Gastroenterology 2022:S0016-5085(22)00149-4. [PMID: 35331440 DOI: 10.1053/j.gastro.2022.02.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Donnelly MC, Stableforth W, Krag A, Reuben A. The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary. J Hepatol 2022:S0168-8278(22)00118-0. [PMID: 35331574 DOI: 10.1016/j.jhep.2022.02.012] [Reference Citation Analysis]
7 Cigrovski Berkovic M, Bilic-Curcic I, Mrzljak A, Cigrovski V. NAFLD and Physical Exercise: Ready, Steady, Go! Front Nutr 2021;8:734859. [PMID: 34676233 DOI: 10.3389/fnut.2021.734859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
8 Orlandi P, Solini A, Banchi M, Brunetto MR, Cioni D, Ghiadoni L, Bocci G. Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals (Basel) 2021;14:995. [PMID: 34681219 DOI: 10.3390/ph14100995] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Sung KC, Hong YS, Lee JY, Lee SJ, Chang Y, Ryu S, Zhao D, Cho J, Guallar E, Lima JAC. Physical activity and the progression of coronary artery calcification. Heart 2021;107:1710-6. [PMID: 34544807 DOI: 10.1136/heartjnl-2021-319346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Della Torre S. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. Cells 2021;10:2502. [PMID: 34572151 DOI: 10.3390/cells10092502] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Kerr CJ, Waterworth SP, Brodie D, Sandercock GRH, Ingle L. The associations between physical activity intensity, cardiorespiratory fitness, and non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021. [PMID: 34427948 DOI: 10.1111/jgh.15672] [Reference Citation Analysis]
12 Machado MV. Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3627-45. [PMID: 34408459 DOI: 10.2147/DMSO.S304357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yamada G, Hagiwara Y, Kimura T, Takeuchi Y, Oba K, Masuda K, Matsuyama Y. Impact of Body Weight Gain on the Incidence of Nonalcoholic Fatty Liver Disease in Nonobese Japanese Individuals. Am J Gastroenterol 2021;116:733-40. [PMID: 33982943 DOI: 10.14309/ajg.0000000000001030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tsai YL, Chen SC. Joint effect of changes in physical activity and weight on incident non-alcoholic fatty liver disease. J Epidemiol Community Health 2021:jech-2021-216728. [PMID: 34088711 DOI: 10.1136/jech-2021-216728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 160] [Article Influence: 12.0] [Reference Citation Analysis]
17 Choi HI, Lee MY, Oh BK, Lee SJ, Kang JG, Lee SH, Lee JY, Kim BJ, Kim BS, Kang JH, Sung KC. Fatty Liver Is Associated with Low N-Terminal Pro-B-Type Natriuretic Peptide in a Healthy Population. J Clin Med 2021;10:1402. [PMID: 33915723 DOI: 10.3390/jcm10071402] [Reference Citation Analysis]
18 Campbell P, Symonds A, Barritt AS 4th. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions. Clin Ther 2021;43:500-17. [PMID: 33583577 DOI: 10.1016/j.clinthera.2021.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Garcêz LS, Avelar CR, Fonseca NSS, Costa PRF, Lyra AC, Cunha CM, Jesus RP, Oliveira LPM. Effect of dietary carbohydrate and lipid modification on clinical and anthropometric parameters in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev 2021:nuaa146. [PMID: 33515021 DOI: 10.1093/nutrit/nuaa146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Dokmak A, Lizaola-Mayo B, Trivedi HD. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. Am J Med 2021;134:23-9. [PMID: 32931760 DOI: 10.1016/j.amjmed.2020.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
22 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 146] [Cited by in F6Publishing: 142] [Article Influence: 73.0] [Reference Citation Analysis]
23 Zou Y, Qi Z. Understanding the Role of Exercise in Nonalcoholic Fatty Liver Disease: ERS-Linked Molecular Pathways. Mediators Inflamm 2020;2020:6412916. [PMID: 32774148 DOI: 10.1155/2020/6412916] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
24 Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37. [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 83] [Article Influence: 11.0] [Reference Citation Analysis]
25 Rhee EJ. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Endocrinol Metab (Seoul) 2019;34:226-33. [PMID: 31565874 DOI: 10.3803/EnM.2019.34.3.226] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
26 Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. Diabetes Metab J 2019;43:127-43. [PMID: 30993937 DOI: 10.4093/dmj.2019.0034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
27 Sung K, Johnston MP, Lee MY, Byrne CD. Non‐invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease. Liver Int 2020;40:1303-15. [DOI: 10.1111/liv.14416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
29 Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic Fatty Liver Disease and Obesity Treatment. Curr Obes Rep 2019;8:220-8. [PMID: 30945129 DOI: 10.1007/s13679-019-00345-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
30 Laitinen TT, Vahtera J, Pahkala K, Magnussen CG, Nuotio J, Hutri-Kähönen N, Kivimäki M, Lehtimäki T, Jokinen E, Laitinen T, Tossavainen P, Pentti J, Viikari JSA, Juonala M, Raitakari OT. Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study. Hepatology 2020;71:67-75. [PMID: 31169929 DOI: 10.1002/hep.30804] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Hernandez Roman J, Patel S. Why Do Lifestyle Recommendations Fail in Most Patients with Nonalcoholic Fatty Liver Disease? Gastroenterol Clin North Am 2020;49:95-104. [PMID: 32033766 DOI: 10.1016/j.gtc.2019.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, Marabotto E, Miele L, Giannini EG. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients 2019;11:E2971. [PMID: 31817398 DOI: 10.3390/nu11122971] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
33 Couzigou P. [Nutritional steatosis a drug target, or more especially anchor point for a holistic approach?]. Presse Med 2019;48:1016-8. [PMID: 31787171 DOI: 10.1016/j.lpm.2019.10.025] [Reference Citation Analysis]
34 Zhong GC, Liu S, Wu YL, Xia M, Zhu JX, Hao FB, Wan L. ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population. PLoS One 2019;14:e0225792. [PMID: 31800606 DOI: 10.1371/journal.pone.0225792] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [DOI: 10.1111/apt.15575] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
36 Mitchell T, McKinnon E, Ayonrinde O, Adams LA, Trinder D, Chua ACG, Newton RU, Straker L, Olynyk JK. Decreased Physical Working Capacity in Adolescents With Nonalcoholic Fatty Liver Disease Associates With Reduced Iron Availability. Clin Gastroenterol Hepatol 2020;18:1584-91. [PMID: 31628998 DOI: 10.1016/j.cgh.2019.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Rust C, Gerbes A. [How to deal with increased liver markers]. MMW Fortschr Med 2017;159:68-70. [PMID: 29124577 DOI: 10.1007/s15006-017-0283-1] [Reference Citation Analysis]
38 Shetty A, Syn W. Current treatment options for nonalcoholic fatty liver disease. Current Opinion in Gastroenterology 2019;35:168-76. [DOI: 10.1097/mog.0000000000000528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
39 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 73] [Article Influence: 17.0] [Reference Citation Analysis]
40 Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol 2019;56:385-96. [PMID: 30519965 DOI: 10.1007/s00592-018-1266-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 16.7] [Reference Citation Analysis]
41 Croci I, Coombes JS, Bucher Sandbakk S, Keating SE, Nauman J, Macdonald GA, Wisloff U. Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. Prog Cardiovasc Dis 2019;62:127-34. [PMID: 30796942 DOI: 10.1016/j.pcad.2019.01.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
42 Li L, Fu J, Sun J, Liu D, Chen C, Wang H, Hou Y, Xu Y, Pi J. Is Nrf2-ARE a potential target in NAFLD mitigation? Current Opinion in Toxicology 2019;13:35-44. [DOI: 10.1016/j.cotox.2018.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Takahashi H, Kotani K, Tanaka K, Egucih Y, Anzai K. Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms. Front Endocrinol (Lausanne). 2018;9:588. [PMID: 30374329 DOI: 10.3389/fendo.2018.00588] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
44 Baranova A, Maltseva D, Tonevitsky A. Adipose may actively delay progression of NAFLD by releasing tumor-suppressing, anti-fibrotic miR-122 into circulation. Obes Rev 2019;20:108-18. [PMID: 30248223 DOI: 10.1111/obr.12765] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
45 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
46 Tomasiewicz K, Flisiak R, Halota W, Jaroszewicz J, Lebensztejn D, Lisik W, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tronina O; Recommendations of the Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD). Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol 2018;4:153-7. [PMID: 30324139 DOI: 10.5114/ceh.2018.78118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
47 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018;68:361-71. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 204] [Cited by in F6Publishing: 184] [Article Influence: 51.0] [Reference Citation Analysis]
48 Wu J, He S, Xu H, Chi X, Sun J, Wang X, Gao X, Wu R, Shao M, Zhao H, Jia J, Wang C, Niu J. Non-alcoholic fatty liver disease incidence, remission and risk factors among a general Chinese population with a 6-year follow-up. Sci Rep 2018;8:7557. [PMID: 29765064 DOI: 10.1038/s41598-018-25641-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
49 Sung KC, Lee MY, Lee JY, Lee SH, Kim JY, Wild SH, Byrne CD. Resolution of fatty liver and weight loss: Independent associations with changes in serum lipids and apolipoproteins. Atherosclerosis 2018;272:47-53. [PMID: 29547708 DOI: 10.1016/j.atherosclerosis.2018.03.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Gerage AM, Ritti-dias RM, Balagopal PB, Conceição RDDO, Umpierre D, Santos RD, Cucato GG, Bittencourt MS. Physical activity levels and hepatic steatosis: A longitudinal follow-up study in adults: Physical activity and hepatic steatosis. Journal of Gastroenterology and Hepatology 2018;33:741-6. [DOI: 10.1111/jgh.13965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
51 Zhong GC, Wu YL, Hao FB, Rao XW, Yuan XW, Zhao Y, Gong JP. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis. J Viral Hepat. 2018;25:842-852. [PMID: 29406564 DOI: 10.1111/jvh.12878] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
52 Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:607-17. [DOI: 10.1016/j.bbadis.2017.11.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
53 Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, McGurnaghan S, McCrimmon R, Read SH, Sattar N, Byrne CD; Scottish Diabetes Research Network Epidemiology Group. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care 2018;41:341-7. [PMID: 29167212 DOI: 10.2337/dc17-1590] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 15.0] [Reference Citation Analysis]
54 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 2734] [Cited by in F6Publishing: 2586] [Article Influence: 683.5] [Reference Citation Analysis]
55 Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med 2018;33:64-74. [PMID: 29202557 DOI: 10.3904/kjim.2017.343] [Cited by in Crossref: 32] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
56 Jan CF, Nfor ON, Huang JY, Hsu SY, Ko PC, Wu MC, Ho CC, Liaw YP. Exercise might prevent cirrhosis in overweight and obese adults. Liver Int 2018;38:515-22. [PMID: 28834113 DOI: 10.1111/liv.13553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
57 Qiu S, Cai X, Sun Z, Li L, Zügel M, Steinacker JM, Schumann U. Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol 2017;10:701-13. [PMID: 28932271 DOI: 10.1177/1756283X17725977] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
58 Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology 2017;65:2100-9. [PMID: 28103626 DOI: 10.1002/hep.29068] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 16.6] [Reference Citation Analysis]
59 Rhee E. Clinical Characteristics of Non-Alcoholic Fatty Liver Disease Based on Analyses from the Kangbuk Samsung Health Study. J Korean Diabetes 2017;18:81. [DOI: 10.4093/jkd.2017.18.2.81] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
60 Kim HS, Ike A, Mathew J. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol 2017;66:664-5. [PMID: 27932209 DOI: 10.1016/j.jhep.2016.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 Zhou D, Hlady RA, Schafer MJ, White TA, Liu C, Choi JH, Miller JD, Roberts LR, LeBrasseur NK, Robertson KD. High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver. Epigenetics 2017;12:55-69. [PMID: 27858497 DOI: 10.1080/15592294.2016.1261239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
62 Keating SE, Adams LA. Exercise in NAFLD: Just do it. J Hepatol 2016;65:671-3. [PMID: 27392426 DOI: 10.1016/j.jhep.2016.06.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]